| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥46.6B | ¥39.4B | +18.2% |
| Operating Income | ¥9.7B | ¥5.9B | +63.8% |
| Ordinary Income | ¥9.6B | ¥5.9B | +63.0% |
| Net Income | ¥6.8B | ¥4.1B | +65.0% |
| ROE | 14.3% | 9.9% | - |
FY2026 Q3 results: Revenue 46.6B yen (YoY +18.2%), Operating Income 9.7B yen (YoY +63.8%), Ordinary Income 9.6B yen (YoY +63.0%), Net Income 6.8B yen (YoY +65.0%). The company achieved substantial profit growth exceeding revenue growth, with operating margin improving to 20.7% from 15.0% in the prior year period. Net profit margin reached 14.5%, supported by strong operational leverage and extraordinary income including gain on sale of investment securities of 4.9B yen. Basic EPS increased 65.5% to 52.24 yen. Total assets expanded to 92.7B yen with equity increasing to 47.2B yen, maintaining a healthy equity ratio of 51.0%. The company's financial profile demonstrates improving profitability metrics alongside solid balance sheet fundamentals, though attention should be paid to the contribution of non-recurring extraordinary gains to net income.
Revenue growth of 18.2% was driven primarily by organic expansion in the animal healthcare services business. Gross profit increased to 19.1B yen with gross margin improving to 40.9% from 35.8% YoY, reflecting operational efficiency gains and favorable business mix. The 2.2B yen increase in gross profit combined with controlled SG&A expense growth resulted in operating income expansion of 3.8B yen. SG&A expenses increased 12.0B yen to 9.4B yen, growing at a slower pace than revenue and representing 20.2% of sales versus 20.8% in the prior period, demonstrating effective cost management and operational leverage.
Non-operating items remained modest with net non-operating expense of 0.04B yen, as non-operating income of 0.3B yen (including dividend income of 1.0B yen) was largely offset by non-operating expenses of 0.3B yen (primarily interest expense of 0.3B yen). Extraordinary items significantly impacted bottom-line results, with extraordinary income of 0.0B yen (including gain on sale of securities of 4.9B yen) and extraordinary losses of 2.3B yen (including loss on valuation of securities of 1.4B yen), resulting in net extraordinary gain of approximately 2.7B yen. This non-recurring net gain contributed substantially to the 65.0% increase in net income.
Income tax expense of 2.9B yen represented an effective tax rate of approximately 29.9%, resulting in net income attributable to owners of 6.8B yen after accounting for 0.2B yen attributable to non-controlling interests. The performance pattern represents revenue growth with accelerated profit growth, driven by operational leverage combined with significant extraordinary gains.
The company operates in a single segment of animal healthcare-related business. Segment-level profitability analysis is not applicable.
[Profitability] ROE of 14.3% demonstrates strong capital efficiency, representing improvement from the implied prior year level of approximately 9.9%. Operating margin of 20.7% expanded 5.7 percentage points from 15.0% YoY, indicating improving operational efficiency. Net profit margin of 14.5% increased from 10.4% YoY, though partially supported by extraordinary gains. Gross margin of 40.9% improved from 35.8% YoY, reflecting favorable business fundamentals. [Cash Quality] Cash and deposits of 12.2B yen provide coverage of 1.77x against short-term debt obligations of 6.9B yen (short-term loans) plus 6.4B yen (current portion of long-term loans), totaling 13.1B yen, demonstrating adequate short-term liquidity with coverage ratio of 0.93x. [Investment Efficiency] Total asset turnover of 0.50 indicates moderate asset utilization efficiency. Property, plant and equipment of 66.0B yen represents 71.2% of total assets, reflecting the capital-intensive nature of the animal healthcare business. [Financial Health] Equity ratio of 51.0% improved from 47.4% YoY, indicating solid financial stability. Current ratio of 108.5% and quick ratio of 103.0% demonstrate adequate short-term solvency. Interest-bearing debt totaled 27.1B yen comprising long-term loans of 26.4B yen and short-term loans of 0.7B yen, with debt-to-equity ratio of 0.57, representing conservative leverage. Interest coverage ratio of approximately 37x (operating income of 9.7B yen divided by interest expense of 0.3B yen) indicates comfortable debt servicing capacity.
Cash and deposits increased 1.2B yen YoY to 12.2B yen, representing 10.5% growth, reflecting profit generation and balance sheet expansion. Working capital movements show accounts receivable increased 0.8B yen to 4.1B yen (+25.2% YoY), growing faster than revenue growth of 18.2%, suggesting slightly extended collection periods that warrant monitoring. Inventories increased 0.2B yen to 0.9B yen (+22.1% YoY), growing at pace with business expansion. Accounts payable increased 0.2B yen to 0.9B yen (+33.7% YoY), indicating improved supplier credit utilization supporting working capital efficiency. The net working capital position shows moderate efficiency with receivables turnover suggesting approximately 32 days sales outstanding. Total assets increased 5.1B yen to 92.7B yen, funded by equity growth of 5.7B yen to 47.2B yen through retained earnings accumulation, while total liabilities declined 0.6B yen to 45.4B yen, demonstrating strengthening financial position. Long-term loans decreased 2.1B yen to 26.4B yen, indicating debt reduction activities. The balance sheet expansion reflects profitable growth with conservative financial management, though formal cash flow statement analysis would provide more definitive assessment of cash generation quality.
Ordinary income of 9.6B yen versus operating income of 9.7B yen indicates net non-operating expense of approximately 0.1B yen, representing minimal divergence between operational and pre-tax results. Non-operating income totaled 0.3B yen, primarily comprising dividend income of 1.0B yen, while non-operating expenses of 0.3B yen consisted mainly of interest expense of 0.3B yen. The net non-operating impact represents less than 1% of revenue, indicating that core profitability is predominantly driven by operating activities. Extraordinary items had material impact with gain on sale of investment securities of 4.9B yen partially offset by loss on valuation of securities of 1.4B yen and other extraordinary losses totaling 0.9B yen, resulting in net extraordinary gain of approximately 2.7B yen representing 5.8% of revenue. These non-recurring items significantly contributed to net income growth of 65.0% compared to operating income growth of 63.8%. The substantial extraordinary gains warrant adjustment when assessing sustainable earnings power. Operating income growth of 63.8% alongside revenue growth of 18.2% demonstrates strong operational leverage and improving core profitability. The divergence between comprehensive income of 6.8B yen and net income of 6.8B yen is minimal, indicating no material other comprehensive income items affecting total equity performance. Overall earnings quality is supported by robust operating income growth, though investors should distinguish between sustainable operational earnings and one-time investment gains when evaluating recurring profit capacity.
Full-year guidance projects revenue of 61.0B yen (YoY +15.6%), operating income of 10.4B yen (YoY +44.2%), and ordinary income of 10.3B yen (YoY +43.0%), with EPS forecast of 56.48 yen and annual dividend of 8.00 yen. Q3 cumulative results show revenue progress rate of 76.4% versus full-year guidance, which exceeds the standard 75% benchmark for Q3, indicating slightly ahead-of-schedule performance. Operating income progress rate of 93.3% substantially exceeds the 75% standard, suggesting strong profit momentum and potential for upside to guidance. The company has not revised its full-year forecast this quarter. Based on Q3 results, achieving full-year targets requires Q4 revenue of approximately 14.4B yen and operating income of 0.7B yen, which appear conservative given Q3 quarterly run-rate performance of 15.5B yen revenue and 3.2B yen operating income. The operating income requirement for Q4 of only 0.7B yen versus Q3 quarterly operating income suggests either highly conservative guidance or anticipated seasonal factors in Q4. Net income guidance of 7.30B yen implies Q4 net income requirement of 0.5B yen, which should be achievable barring significant extraordinary losses. The forecast assumes EPS of 56.48 yen on average shares outstanding of approximately 12.9 million. No forward-looking assumptions regarding extraordinary items or specific business drivers are explicitly disclosed in the forecast notes, though management cautions that forecasts are based on currently available information and certain assumptions.
The company declared year-end dividend of 37.00 yen per share with no interim dividend, resulting in annual dividend of 37.00 yen. However, dividend notes indicate that a 5-for-1 stock split was executed on December 17, 2025, and the stated dividend of 37.00 yen represents pre-split basis. The full-year dividend forecast of 8.00 yen appears to reflect post-split basis. Calculating payout ratio based on reported figures: annual dividend of 37.00 yen versus basic EPS of 52.24 yen yields payout ratio of 70.8%. If the forecast dividend of 8.00 yen on post-split basis is compared to forecast EPS of 56.48 yen, the implied payout ratio is 14.2%. The apparent discrepancy warrants clarification, though the dividend notes suggest that actual shareholder returns should be evaluated on post-split adjusted basis. Based on net income of 6.8B yen and average shares outstanding of 12.9 million, the total dividend payment would represent approximately 4.8B yen at 37.00 yen per share pre-split (or equivalent post-split), yielding payout ratio of approximately 70% of net income. This represents substantial shareholder returns, though sustainability should be assessed against operating cash flow generation once cash flow statement becomes available. No share buyback activities are disclosed in the current period data.
Business concentration risk: Operating as a single-segment animal healthcare business exposes the company to sector-specific demand fluctuations, regulatory changes, and competitive dynamics without diversification benefits across multiple business lines. Changes in pet ownership trends, veterinary service utilization patterns, or industry regulations could materially impact consolidated performance.
Financial leverage and debt refinancing risk: Total interest-bearing debt of 27.1B yen comprises primarily long-term loans of 26.4B yen, with current portion of 6.4B yen requiring refinancing or repayment within one year. While interest coverage ratio of 37x indicates comfortable debt servicing capacity, the company's ability to refinance maturing debt on favorable terms depends on maintaining profitability and credit market conditions.
Working capital efficiency risk: Accounts receivable increased 25.2% YoY compared to revenue growth of 18.2%, indicating collection period extension. Accounts payable increased 33.7% YoY, suggesting increased reliance on trade credit. These working capital trends warrant monitoring as continued divergence from revenue growth rates could pressure cash conversion efficiency and require additional working capital investment to support growth.
[Industry Position] (Reference - Proprietary Analysis)
The company operates in animal healthcare services, which may share certain operational characteristics with service-oriented businesses. For reference purposes, comparison with IT and Telecom sector benchmarks (as proxy for service business metrics) provides the following perspective: Profitability metrics show operating margin of 20.7% substantially exceeds the IT/Telecom industry median of 8.2% (2025-Q3, IQR: 3.6%-18.0%, n=104), positioning the company in the upper quartile for operational efficiency. ROE of 14.3% exceeds industry median of 8.3% (IQR: 3.6%-13.1%, n=104), indicating superior capital efficiency. Net profit margin of 14.5% significantly outperforms industry median of 6.0% (IQR: 2.2%-12.7%, n=104), though investors should note the contribution of extraordinary gains to this metric.
Financial health metrics show equity ratio of 51.0% approaches industry median of 59.2% (IQR: 42.5%-72.7%, n=104), representing solid but not exceptional financial stability relative to sector. Current ratio of 1.09x is below industry median of 2.15x (IQR: 1.57x-3.62x, n=94), suggesting tighter short-term liquidity management compared to sector peers. Financial leverage of 1.96x exceeds industry median of 1.66x (IQR: 1.36-2.32, n=104), indicating moderately higher leverage utilization. Efficiency metrics include asset turnover of 0.50 below industry median of 0.67 (IQR: 0.49-0.93, n=104), reflecting the capital-intensive nature of the business with significant property, plant and equipment holdings representing 71% of total assets.
Growth metrics show revenue growth of 18.2% exceeds industry median of 10.4% (IQR: -1.1%-19.5%, n=103), positioning the company favorably for top-line expansion. However, direct industry comparison should be interpreted cautiously as the animal healthcare business may exhibit different operational and financial characteristics than IT/Telecom reference group. (Source: Proprietary analysis)
Strong operational leverage driving accelerated profit growth: Operating income growth of 63.8% substantially exceeding revenue growth of 18.2% demonstrates powerful operational leverage, with operating margin expansion of 5.7 percentage points to 20.7% indicating improving business fundamentals. The company achieved this through gross margin improvement to 40.9% combined with SG&A expense discipline, suggesting scalability of the business model and potential for continued margin expansion as revenue grows.
Material contribution from non-recurring extraordinary gains requires adjustment: Net income growth of 65.0% benefited from extraordinary gain on sale of investment securities of 4.9B yen and net extraordinary items totaling approximately 2.7B yen. Adjusting for these one-time items, normalized operating earnings demonstrate sustainable profitability improvement, though investors should distinguish between recurring operational earnings power and investment portfolio gains when assessing forward earnings expectations and valuation multiples.
Conservative balance sheet with adequate liquidity and manageable leverage: Equity ratio of 51.0% combined with interest coverage of 37x indicates strong financial stability and debt servicing capacity. However, current ratio of 108.5% and cash coverage of short-term obligations at 0.93x suggest tighter working capital management compared to industry benchmarks, warranting monitoring of cash conversion efficiency. The company's debt reduction activities (long-term loans decreased 2.1B yen YoY) alongside equity growth through retained earnings demonstrate conservative financial management, providing flexibility for growth investments while maintaining financial stability.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.